QuarterWatch Monitoring FDA MedWatch Reports Why Reports of Serious Adverse Drug Events Continue to Grow October 3, 2012 Data from 2012 Quarter 1

First Page		Document Content
Date: 2012-10-03 12:53:27 Food and Drug Administration Clinical research Thiophenes Healthcare quality Medical terminology Adverse Event Reporting System Duloxetine Pharmacovigilance Rivaroxaban Adverse effect Adverse event MedWatch		QuarterWatch Monitoring FDA MedWatch Reports Why Reports of Serious Adverse Drug Events Continue to Grow October 3, 2012 Data from 2012 Quarter 1 Add to Reading List Source URL: www.ismp.org Download Document from Source Website File Size: 406,52 KB Share Document on Facebook

	* Drug Safety Alert * Xarelto (Rivaroxaban) Tablets FDA MedWatch - August 2013 Safety Labeling Changes with revisions to Prescribing Information [PostedThe MedWatch August 2013 Safety Labeling Changes po DocID: 1t7rk - View Document
	Microsoft Word - frommtg draft uspi xarelto rivaroxaban.doc DocID: 1sPZ1 - View Document
	MEDICATION GUIDE XARELTO® (zah-REL-toe) (rivaroxaban) tablets Read this Medication Guide before you start taking XARELTO and each time you get a refill. There may be new information. This Medication Guide does not take DocID: 1scq8 - View Document
	Atrial Fibrillation (AFib) Treatment Adherence Following your treatment plan will reduce your risk of AFib-related stroke. it can enter the bloodstream and cause a stroke. A stroke means DocID: 1pjDF - View Document
	QuarterWatch Monitoring FDA MedWatch Reports Why Reports of Serious Adverse Drug Events Continue to Grow October 3, 2012 Data from 2012 Quarter 1 DocID: 1p1ui - View Document